Essay --

IntroductionWe are experiencing unprecedented rates of biodiversity loss. 60% of the ecosystem services (such as freshwater, fisheries, pollination and climate regulation) which biodiversity underpins are either adulterated or in decline. Predictions are that this trend will worsen. It is clear that it has stern economic implications, not only for society but also for calling as most industries depend on ecosystem services to function. The pharmaceutical vault of heaven is both dependent on and impacts on biodiversity and ecosystem services or BES. well-nigh 25% to 50% of the pharmaceutical market is derived from active ingredients from nature. The sectors dependence on the BES stems from the mathematical function of active ingredients from nature in do drugs discovery and manufacture, the use of water and a reliance on idle fond materials such as fish petroleums, soya and palm oil in drug manufacturer. Impacts include water pollution from drug manufacturing and use, overuse of active ingredients from nature that cant readily be synthesized and use of inert ingredients linked with environmental degradation.For the pharmaceutical sector, this may pose reputational, operational, restrictive and market risks as well as rude(a) opportunities linked to new drug discovery. Pharmaceutical industry investors may also face reputational and monetary risks if the companies in which they invest do not adequately manage their give BES risks.All companies reviewed have started to consider the business implications of declining BES. However, none are managing the BES in a comprehensive manner. The focus of corporate activity has been on consciousness site-level impacts on biodiversity such as risks associated with potential impacts on protected areas or water consump... ...e to determine company risk exposure in intercourse to BES. Lack of information on how companies are managing their risks and opportunities leads to decreased investor confidence. Companies s hould be promote to disclose more information on volume, nature and provenance of raw materials sourced, the outcomes of products and issue risk assessments and the activities underway to address them, if that assessment shows them to be material. Referenceshttp//www.deadiversion.usdoj.gov/drug_disposal/index.html register///C/Users/De/Desktop/Media_release_-_pharmaceutical_companies_face_biodiversity_risk.pdfhttp//www.naturalvalueinitiative.org/content/010/102.phphttp//www.cefic.org/Documents/IndustrySupport/RC%20tools%20for%20SMEs/Document%20Tool%20Box/Biodiversity-and-Ecosystem-services_What-are-they-all-about.pdfBiodiversity and Human Health By Jensa Bell